A team of researchers in Philadelphia, including former Damon Runyon Scholar Mark A. Lemmon, PhD, announced that the recently-approved lung cancer drug crizotinib (Xalkori) could potentially be used to treat neuroblastoma patients. The most common cancer among infants, neuroblastoma is a disease of the developing nerve cells. Treatment options are currently limited to surgery and chemotherapy.

> Read the whole post: “Lung Cancer Drug Shows Promise Against Neuroblastoma”